|
Dr. Thornton serves as Senior Vice President of Product Development. Dr. Thornton, a Clinical Pharmacologist and Trialist, has divided his 15-year career at FDA and in the biotechnology industry equally between oncology and infectious disease biologics clinical development. At the FDA, he was on the clinical review team for Erbitux(R) for its initial colon cancer indication, and Pegasys(R) for its Hepatitis C indication. At the FDA he also led the initial efforts to establish the FDA Gene Therapy Patient Tracking System and published on the topic of optimizing regulatory pathways for cancer vaccines. In industry, Dr. Thornton has performed Phase I-III clinical trials in both oncology and infectious disease settings, and successfully submitted PLAs for Certiva(TM) while at North American Vaccine and WinRho(R) while at Univax Biologics. | 